Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from JAMA Neurology Author Interviews
Acoustic Analysis of Primary Care Patient–Clinician Conversations to Screen for Cognitive Impairment
Phenoconversion in Pure Autonomic Failure
Brain Biomarkers and a Multidomain Lifestyle Intervention
Epstein-Barr Virus Antibodies and Multiple Sclerosis
Get summaries like this every morning.
Free AI-powered recaps of JAMA Neurology Author Interviews and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.